CJC-1295 (no DAC)vsTB-500

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

TB-500 is the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide present in virtually every nucleated cell in the body. Its central molecular function is the sequestration of G-actin monomers — the globular, unpolymerized form of actin. By binding G-actin at a 1:1 ratio, TB-500 maintains a reservoir of monomeric actin that can be rapidly mobilized for polymerization into F-actin filaments when cells need to migrate, change shape, or form new structures during tissue repair.

This actin-regulating role is fundamental to TB-500's healing effects. When tissue is damaged, cells at the wound margin must migrate into the injury site. Cell migration requires dynamic actin polymerization at the leading edge of the cell (forming lamellipodia and filopodia) and depolymerization at the trailing edge. TB-500 facilitates this process by providing a controlled supply of G-actin monomers. It promotes migration of keratinocytes (for skin wound closure), endothelial cells (for new blood vessel formation), and cardiac progenitor cells (for heart repair).

Beyond actin regulation, TB-500 has significant anti-inflammatory and gene-regulatory effects. It downregulates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α while upregulating anti-inflammatory mediators. It activates cell survival pathways, specifically Akt-mediated anti-apoptotic signaling, protecting damaged cells from programmed cell death. TB-500 also promotes angiogenesis by stimulating endothelial progenitor cell differentiation and new capillary formation. In cardiac tissue, it has demonstrated the ability to activate epicardial progenitor cells and promote cardiomyocyte survival following ischemic injury. The combination of cell migration, anti-inflammation, angiogenesis, and cell survival makes TB-500 one of the most broad-spectrum healing peptides available.